Health Catalyst(US:HCAT)2026-03-12 22:00Financial Data and Key Metrics Changes - For the full year of 2025, the company generated $311.1 million in revenue and $41.4 million of Adjusted EBITDA, with total revenue for Q4 2025 at $74.7 million, down from $79.6 million in the prior year period [15][16] - Adjusted gross margin for Q4 2025 was 53.5%, compared to 46.6% in the prior year period, while for the full year, it was 51.1% [17] - Adjusted operating expenses for Q4 2025 were $26.2 million, representing 35% of revenue, down from 37% in Q4 2024 [17][18] - The company incurred impairment charges on goodwill and intangible assets of $110.2 million during 2025, leading to a GAAP net loss of $178 million, up from a loss of $69.5 million in 2024 [18][19] Business Line Data and Key Metrics Changes - Technology revenue for Q4 2025 was $51.9 million, while professional services revenue was $22.8 million, with the decline in professional services attributed to reduced FTE service offerings [16] - For the full year, technology revenue increased by 7% year-over-year to $208.3 million, while professional services revenue declined by 8% [16] Market Data and Key Metrics Changes - The company finished the year with 32 net new logos, ahead of the target of 30 but below the initial expectation of 40 [15] - The dollar-based retention rate for technology plus TAMS closed the year at 93% [15] Company Strategy and Development Direction - The company is focused on tightening leadership and execution discipline, with plans to strengthen operational rigor and clarify market positioning [6][7] - A renewed focus on simplifying the commercial engine to drive technology ARR bookings and improve retention through predictable migrations is emphasized [11][12] - The company aims to leverage its intellectual property and expertise in AI to solve pressing healthcare problems [11][12] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the challenging market conditions for clients, emphasizing the need for better cost management and clinical quality [43][46] - The company is currently in an assessment mode regarding its strategic positioning and potential opportunities for shareholder value [28][31] - Guidance for Q1 2026 revenue is expected to be between $68 million and $70 million, with Adjusted EBITDA of $7 million to $8 million [20] Other Important Information - The company is reviewing its cost structure to ensure strategic capital allocation and is focused on expanding technology bookings and margins [8][12] - The company is not yet in a position to provide full-year guidance for 2026 but plans to offer more clarity in the next earnings call [14][64] Q&A Session Summary Question: Does the strategic review include the possibility of selling the company? - Management is focused on positioning the company for long-term success and creating shareholder value, but no definitive answer was provided regarding a sale [27][28][31] Question: Can you elaborate on the transition impact and the $52 million in data platform revenue at risk? - The $52 million encompasses both integrated applications and data platform infrastructure, with the latter facing the highest pressure during the migration [34][35] Question: What insights were gained regarding bookings and demand in Q4? - The market is under pressure to manage costs and improve clinical quality, which is reflected in the demand for the company's solutions [41][43] Question: How does the company plan to maintain margins amid revenue pressure? - There is expected pressure on gross margins due to migration costs, but these are anticipated to be removed post-migration [61][63] Question: Can you break down the $12.5 million in ARR churn and its impact on 2026? - Approximately 75% of the $12.5 million is expected to impact 2026, with more details to be provided in the upcoming guidance [68][70]